Edesa Biotech prices USD 25 million follow-on offering at USD 5.5 per unit
Reuters2026/08/20 02:20- Edesa Biotech priced a USD 25 million underwritten public offering of common shares, pre-funded warrants, common share warrants.
- Deal includes 3,870,500 common shares with matching common share warrants, priced at USD 5.5 per share-warrant package.
- Also offers pre-funded warrants for up to 675,000 shares with matching common share warrants, priced at USD 5.4999 per package.
- Common share warrants carry a USD 7.5 exercise price, expire in 18 months or 30 days after Phase 2 EB06 vitiligo topline data.
- Underwriters received a 30-day option for 681,825 additional shares with matching common share warrants; closing expected about Aug. 21, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GBP/USD Price Forecast: Consolidates below mid-1.3500s; bullish potential seems intact
Singapore Index Fund NAV per unit at S$ 5.44 as of Sept. 7, 2026
PT Bersama Mencapai Puncak releases transcript of 2026 incidental public expose
Apple Rarely Signs 3-5 Year NAND Long-Term Contracts, May Not Set Price Cap; AI Squeezes Capacity, Shifting Bargaining Power in Storage
Apple is negotiating a 3-5 year long-term NAND flash memory contract with Kioxia, potentially without a price cap. This marks a shift in its procurement strategy from "lower prices and multiple sources" to "volume lock-in and long-term contracts." The change is driven by fierce competition among AI data center clients for storage capacity, forcing Apple to prioritize supply security. Pricing power for storage chips is shifting from buyers to sellers, and the duration of this storage cycle may exceed traditional market expectations.
Crypto prices
More
